Skip to main content
36°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Travere Therapeutics, Inc. - Common Stock
(NQ:
TVTX
)
19.27
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
19.27
Bid (Size)
14.95 (6)
Ask (Size)
21.50 (2)
Prev. Close
19.27
Today's Range
19.27 - 19.27
52wk Range
5.120 - 25.29
Shares Outstanding
60,717,176
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 12, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Analyst Expectations For Travere Therapeutics's Future
February 24, 2025
Via
Benzinga
Performance
YTD
+1.58%
+1.58%
1 Month
-8.67%
-8.67%
3 Month
+3.16%
+3.16%
6 Month
+57.43%
+57.43%
1 Year
+148.65%
+148.65%
More News
Read More
Travere Therapeutics to Participate at Upcoming Investor Conferences
February 24, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
February 20, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For February 20, 2025
February 20, 2025
Via
Benzinga
A Preview Of Travere Therapeutics's Earnings
October 30, 2024
Via
Benzinga
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
February 13, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 12, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Sparks Retail Frenzy As Stock Hits Over 2-Year High On FDA Approval Plan For Kidney-Disease Drug
February 11, 2025
Via
Stocktwits
Exposures
Product Safety
Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug
February 11, 2025
Via
Investor's Business Daily
Exposures
Product Safety
Lattice Semiconductor, SelectQuote, Radiant Logistics And Other Big Stocks Moving Higher On Tuesday
February 11, 2025
Via
Benzinga
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
February 11, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Provides Corporate Update and 2025 Outlook
January 13, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
January 09, 2025
Via
Investor's Business Daily
Topics
Artificial Intelligence
Government
Exposures
Artificial Intelligence
Political
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
November 25, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 13, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
November 12, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
3 Under-the-Radar Healthcare Companies
November 11, 2024
Via
MarketBeat
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
November 07, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Announces Proposed Public Offering of Common Stock
November 07, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
November 04, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Third Quarter 2024 Financial Results
October 31, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
October 26, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'
October 23, 2024
Via
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
